Slide 1: 4Q & Full-Year Fiscal 2023 Webcast
4Q & Full-Year Fiscal 2023 Webcast December 14, 2023 NBS NEXT OWNER MINDSET WINNING TEAMS
Slide 2: Safe Harbor Statement
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as
Slide 3: Agenda
Agenda 4Q and Full-Year Fiscal 2023 Webcast – December 14, 2023 4th Quarter and Full-Year Highlights Enterprise Performance Sales Performance and Earnings Review FY 2024 and 1Q 2024 Guidance Balance Sheet and Cash Flow Q&A Sundaram Nagarajan Joseph Kelley Stephen Shamrock Lara Mahoney Pr
Slide 4: Highlights
Highlights Strong execution and Ascend Strategy on track to achieve NBS Next driving record sales $3 billion in sales and 30%+ and EBITDA EBITDA margins by fiscal 2025 FY 2023 Results: Record sales 31% EBITDA Margin Record cash flow Solid result in dynamic environment 4
Slide 5: Total Company – 4Q 2023
Total Company – 4Q 2023 Sales Reported sales increased 5% 7% acquisitive growth and favorable currency of 1% Organic decrease of 3% driven by electronics dispense and biopharma EBITDA* 4Q 2022 4Q 2023 ∆ EBITDA was quarterly record of $227 million, 32% of Sales $683.6 $719.3 5% sales; 200 bas
Slide 6: Total Company – Fiscal 2023
Total Company – Fiscal 2023 Record Annual Sales Annual sales of $2.6 billion, an increase of 2% 4% growth driven by the CyberOptics and ARAG acquisitions, 1% decrease in both organic volume and currency EBITDA* EBITDA was a record $819 million, 31% of sales FY 2022 FY 2023 ∆ EBITDA increased
Slide 7: Industrial Precision Solutions – 4Q 2023
Industrial Precision Solutions – 4Q 2023 Sales Sales of $405 million, a 14% sales increase 4% organic growth; 7% acquisition; 2% favorable currency impact Record sales driven by industrial coatings, polymer processing and packaging product lines Strong system sales in the Americas and Asia P
Slide 8: Medical and Fluid Solutions – 4Q 2023
Medical and Fluid Solutions – 4Q 2023 Sales Sales of $169 million, decrease of 7% Organic decrease of 8%, slightly offset by a favorable currency impact of 1% Organic sales decrease was driven by medical fluid components and fluid solutions product lines EBITDA* EBITDA and Margin EBITDA was
Slide 9: Advanced Technology Solutions – 4Q 2023
Advanced Technology Solutions – 4Q 2023 Sales Sales of $145 million, decrease of 1% 16% organic decline; 15% acquisition Organic sales decline was driven by softness in products serving the semiconductor market EBITDA* EBITDA and Margin $40 EBITDA was $35 million, or 24% of sales $35 26% 24%
Slide 10: Balance Sheet and Cash Flow
Balance Sheet and Cash Flow Strong Cash Flow with Sufficient Liquidity to Invest in Strategic Initiatives Free Cash Flow Net Debt Q4 cash flow of $153 million, leading to record free Cash totaled $116 million cash flow of $607 million in fiscal 2023 2.0 net debt leverage ratio based on trailin
Slide 11: NBS Next Owner Mindset Winning Teams
NBS Next Owner Mindset Winning Teams Investing in the best Empowered leaders Developing winning organic growth making decisions close teams at each level of opportunities to the customer the organization Customer needs and Agile, operational Right balance between simplicity driving new e
Slide 12: 2024 Fiscal Full-Year Guidance
2024 Fiscal Full-Year Guidance Full-Year Sales Guidance Full-Year Growth from Record 2023 $2,629 $2,725 - $2,855 $2,590 Ascend strategy is advancing and delivering results Backlog, including ARAG, is ~$800 million Fiscal 2024 sales growth of 4% to 9% Adjusted earnings in the range of 1% to 8
Slide 13: 2024 Fiscal 1Q Guidance
2024 Fiscal 1Q Guidance 1Q 2024 Sales Guidance Steady performance moving into 1Q $615 - $640 $609 $610 1Q 24 sales of $615 - $640 million 1Q 24 adjusted earnings per share in the range of $2.00 - $2.10 Increased interest expense is ~$0.15 per share headwind in 1Q 24 1Q22 1Q23 1Q24 1Q 2024 Adju
Slide 14: Questions?
Questions? Giordson
Slide 15: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures Adjusted Operating Profit and EBITDA (Dollars in thousands) 15
Slide 16: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures Profitability (Dollars in thousands) 16
Slide 17: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures Profitability (Dollars in thousands) Starting in fiscal 2024, the Company’s definition of adjusted earnings will exclude acquisition related amortization for both current and historical periods. Historical periods for 2022 and 2023 listed here for reference. 17